Background: Lung cancer kills the most people worldwide. Most Bangladeshi patients had regionally advanced surgically inoperable Non-Small Cell Lung Cancer (NSCLC), a deadly disease. Radiotherapy to main tumor and regional lymphatics with chemotherapy is conventional treatment. Objective: This study was done to investigate the symptoms relief and treatment related toxicities in hypo fractionated 17 Gy in 2 fractions which is effectively comparable to 30 Gy in 10 fractions. Methods: A total 60 patients were divided equally into Arm A and Arm B with locally advanced stage IIIA, and stage IIIB NSCLC patients with the objective to compare palliation of symptoms and to assess the toxicity profile. This Quasi Experimental study was carried out from January 2018 to December 2018 in the department of Radiation oncology, National Institute of Cancer Research and Hospital. Cases of Arm A were treated with 17 Gy radiotherapy in 2 fractions and those of Arm B were treated with 30 Gy radiotherapy in 10 fractions. Results: The mean age was 49.3±8.8 and 52.2±8.1 years for the Arm- A and the Arm-B respectively. Most patients in both groups were males, 80% in group A and 90% in group B. Adenocarcinoma (Arm A-70%, Arm B- 66.7%) was the most common pathological subtype in both groups, followed by Squamous cell carcinoma (30%, 33.3% respectively). This study showed that there was a significant palliation of these symptoms following radiotherapy as reported by patients and as assessed clinically with no statistically significant difference between two Arms. Hemoptysis had the highest rate of improvement, 100% in both arms and improvement in chest pain by 83.3% in arm A and 70% in Arm B. Cough was improved in 83.3% and 67.7% and dyspnea was palliated in 80.0% and 70.0% of patients in Arm A and Arm B, respectively as per clinical assessment of the patients. The early toxicities in both arms had no significant difference. Patients with locally advanced inoperable NSCLC have poor prognosis and less survival. The first goal was acceptable symptoms control as cough, dyspnoea, haemoptysis and chest pain. Conclusion: The result of this study showed that a significant palliation of symptoms with minimum toxicities improving quality of life following radiotherapy as reported by patients also assessed clinically and radiographically with no statistically significant difference among both arms.
| Published in | International Journal of Clinical Oncology and Cancer Research (Volume 8, Issue 2) |
| DOI | 10.11648/j.ijcocr.20230802.11 |
| Page(s) | 20-26 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Hypofractionated Palliative Radiotherapy, Lung Cancer, Toxicities
| [1] | Cancer [Internet]. Who. int. [cited 2022 Oct 17]. Available from: http://www.who.int/news-room/fact-sheets/detail/cancer |
| [2] | Sundstrøm, S., Bremnes, R., Aasebø, U., Aamdal, S., Hatlevoll, R., Brunsvig, P et al. 2004. Hypofractionated palliative radiotherapy (17 gy per two fractions) in advanced non–small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. Journal of clinical oncology, 22 (5), pp. 801-810. |
| [3] | Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S. et al., 2004. American Society of Clinical Oncology treatment of unresectable non–small-cell lung cancer guideline: Update 2003. Journal of Clinical Oncology, 22 (2), pp. 330-353. |
| [4] | Mountain, C. F., 1997. Revisions in the international system for staging lung cancer. Chest, 111 (6), pp. 1710-1717. |
| [5] | Langendijk, J. A., Ten Velde, G. P. M., Aaronson, N. K., De Jong, J. M. A., Muller, M. J. and Wouters, E. F. M., 2000. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. International Journal of Radiation Oncology* Biology* Physics, 47 (1), pp. 149-155. |
| [6] | Martin C. S. Wong, Xiang Qian Lao, Kin-Fai Ho, William B. Goggins & Shelly L. A. Tse., 2017. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Scientific Reports, 7. |
| [7] | Zaman, M. M., Nargis, N., Perucic, A. M. and Rahman, K., 2007. Impact of tobacco related illness in Bangladesh. SEARO, WHO, New Delhi. |
| [8] | Cancer Registry Report, National Institute of Cancer Research and Hospital, 2014. |
| [9] | Cancer Registry Report 2010, National Institute of Cancer Research and Hospital, Dhaka, 2008-2010. |
| [10] | Parkin, D. M., Pisani, P., Lopez, A. D. and Masuyer, E., 1994. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. International journal of cancer, 59 (4), pp. 494-504. |
| [11] | Medical Research Council Lung Cancer Working Party, 1991. Inoperable non-small cell lung cancer (NSCLC): A Medical Research Council randomized trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer, 63, pp. 265-270. |
| [12] | Ferlay J., Shin H. R., Bray F., Forman D., Mathers C. and Parkin D. M.: GLOBOCAN 2008 v1. 2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet] Lyon, France: International Agency for Research on Cancer, 2010. Available from: http://globocan.iarc.fr. Accessed May 2011. |
| [13] | Inoperable non-small-cell lung cancer (NSCLC) 1991: a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer. 63 (2), pp. 265-270. |
| [14] | Cross, C. K., Berman, S., Buswell, L., Johnson, B. and Baldini, E. H., 2004. Prospective study of palliative hypofractionated radiotherapy (8.5 Gy× 2) for patients with symptomatic non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 58 (4), pp. 1098-1105. |
| [15] | ASRTO 2016 : Hypofractionated radiation therapy may halve treatment time for lung cancer patient with poor performance status. |
| [16] | Stephens, R. J., Hopwood, P. and Girling, D. J., 1999. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. British journal of cancer, 79 (3), pp. 538–544. |
| [17] | Senkus-Konefka, E., Dziadziuszko, R., Bednaruk-Młyński, E., Pliszka, A., Kubrak, J., Lewandowska, A., et al., 2005. A prospective, randomised study to compare two palliative radiotherapy schedules for non-small-cell lung cancer (NSCLC). British journal of cancer, 92 (6), pp. 1038–1045. |
| [18] | Teo, P., Tai, T. H., Choy, D. and Tsui, K. H., 1988. A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. International Journal of Radiation Oncology Biology Physics, 14 (5), pp. 867-871. |
| [19] | Bezjak, A., Dixon, P., Brundage, M., Tu, D. S., Palmer, M. J., Blood, P. et al., 2002. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC. 15). International Journal of Radiation Oncology Biology Physics, 54 (3), pp. 719-728. |
| [20] | Socinski, M. A., Morris, D. E., Masters, G. A. and Lilenbaum, R., 2003. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest, 123 (1), pp. 226S-243S. |
| [21] | Kramer, G. W. P. M., Wanders, S. L., Noordijk, E. M., Vonk, E. J., van Houwelingen, H. C., van den Hout, W. B et al., 2005. Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. Journal of clinical oncology, 23 (13), pp. 2962-2970. |
| [22] | Sause, W. T., Scott, C., Taylor, S., Johnson, D., Livingston, R., Komaki, R., Emami, B., Curran, W. J., Byhardt, R. W., Turrisi, A. T. and Dar, A. R., 1995. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. JNCI: Journal of the National Cancer Institute, 87 (3), pp. 198-205. |
APA Style
Kamrun Nahar Tania, Jannatun Nisa, Moarraf Hossen, Muhammad Masudul Hassan Arup, Muhammad Abdullah-Al-Noman, et al. (2023). Comparative Study of Hypofractionated Palliative Radiotherapy 17 Gy in 2 Fractions vs. 30 Gy in 10 Fractions in Lethal Locally Advanced Non-small Cell Lung Cancer. International Journal of Clinical Oncology and Cancer Research, 8(2), 20-26. https://doi.org/10.11648/j.ijcocr.20230802.11
ACS Style
Kamrun Nahar Tania; Jannatun Nisa; Moarraf Hossen; Muhammad Masudul Hassan Arup; Muhammad Abdullah-Al-Noman, et al. Comparative Study of Hypofractionated Palliative Radiotherapy 17 Gy in 2 Fractions vs. 30 Gy in 10 Fractions in Lethal Locally Advanced Non-small Cell Lung Cancer. Int. J. Clin. Oncol. Cancer Res. 2023, 8(2), 20-26. doi: 10.11648/j.ijcocr.20230802.11
AMA Style
Kamrun Nahar Tania, Jannatun Nisa, Moarraf Hossen, Muhammad Masudul Hassan Arup, Muhammad Abdullah-Al-Noman, et al. Comparative Study of Hypofractionated Palliative Radiotherapy 17 Gy in 2 Fractions vs. 30 Gy in 10 Fractions in Lethal Locally Advanced Non-small Cell Lung Cancer. Int J Clin Oncol Cancer Res. 2023;8(2):20-26. doi: 10.11648/j.ijcocr.20230802.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcocr.20230802.11,
author = {Kamrun Nahar Tania and Jannatun Nisa and Moarraf Hossen and Muhammad Masudul Hassan Arup and Muhammad Abdullah-Al-Noman and Mohammad Shaiful Hassan Shameem and Sonya Begum and Mohammad Arifur Rahman},
title = {Comparative Study of Hypofractionated Palliative Radiotherapy 17 Gy in 2 Fractions vs. 30 Gy in 10 Fractions in Lethal Locally Advanced Non-small Cell Lung Cancer},
journal = {International Journal of Clinical Oncology and Cancer Research},
volume = {8},
number = {2},
pages = {20-26},
doi = {10.11648/j.ijcocr.20230802.11},
url = {https://doi.org/10.11648/j.ijcocr.20230802.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20230802.11},
abstract = {Background: Lung cancer kills the most people worldwide. Most Bangladeshi patients had regionally advanced surgically inoperable Non-Small Cell Lung Cancer (NSCLC), a deadly disease. Radiotherapy to main tumor and regional lymphatics with chemotherapy is conventional treatment. Objective: This study was done to investigate the symptoms relief and treatment related toxicities in hypo fractionated 17 Gy in 2 fractions which is effectively comparable to 30 Gy in 10 fractions. Methods: A total 60 patients were divided equally into Arm A and Arm B with locally advanced stage IIIA, and stage IIIB NSCLC patients with the objective to compare palliation of symptoms and to assess the toxicity profile. This Quasi Experimental study was carried out from January 2018 to December 2018 in the department of Radiation oncology, National Institute of Cancer Research and Hospital. Cases of Arm A were treated with 17 Gy radiotherapy in 2 fractions and those of Arm B were treated with 30 Gy radiotherapy in 10 fractions. Results: The mean age was 49.3±8.8 and 52.2±8.1 years for the Arm- A and the Arm-B respectively. Most patients in both groups were males, 80% in group A and 90% in group B. Adenocarcinoma (Arm A-70%, Arm B- 66.7%) was the most common pathological subtype in both groups, followed by Squamous cell carcinoma (30%, 33.3% respectively). This study showed that there was a significant palliation of these symptoms following radiotherapy as reported by patients and as assessed clinically with no statistically significant difference between two Arms. Hemoptysis had the highest rate of improvement, 100% in both arms and improvement in chest pain by 83.3% in arm A and 70% in Arm B. Cough was improved in 83.3% and 67.7% and dyspnea was palliated in 80.0% and 70.0% of patients in Arm A and Arm B, respectively as per clinical assessment of the patients. The early toxicities in both arms had no significant difference. Patients with locally advanced inoperable NSCLC have poor prognosis and less survival. The first goal was acceptable symptoms control as cough, dyspnoea, haemoptysis and chest pain. Conclusion: The result of this study showed that a significant palliation of symptoms with minimum toxicities improving quality of life following radiotherapy as reported by patients also assessed clinically and radiographically with no statistically significant difference among both arms.},
year = {2023}
}
TY - JOUR T1 - Comparative Study of Hypofractionated Palliative Radiotherapy 17 Gy in 2 Fractions vs. 30 Gy in 10 Fractions in Lethal Locally Advanced Non-small Cell Lung Cancer AU - Kamrun Nahar Tania AU - Jannatun Nisa AU - Moarraf Hossen AU - Muhammad Masudul Hassan Arup AU - Muhammad Abdullah-Al-Noman AU - Mohammad Shaiful Hassan Shameem AU - Sonya Begum AU - Mohammad Arifur Rahman Y1 - 2023/05/10 PY - 2023 N1 - https://doi.org/10.11648/j.ijcocr.20230802.11 DO - 10.11648/j.ijcocr.20230802.11 T2 - International Journal of Clinical Oncology and Cancer Research JF - International Journal of Clinical Oncology and Cancer Research JO - International Journal of Clinical Oncology and Cancer Research SP - 20 EP - 26 PB - Science Publishing Group SN - 2578-9511 UR - https://doi.org/10.11648/j.ijcocr.20230802.11 AB - Background: Lung cancer kills the most people worldwide. Most Bangladeshi patients had regionally advanced surgically inoperable Non-Small Cell Lung Cancer (NSCLC), a deadly disease. Radiotherapy to main tumor and regional lymphatics with chemotherapy is conventional treatment. Objective: This study was done to investigate the symptoms relief and treatment related toxicities in hypo fractionated 17 Gy in 2 fractions which is effectively comparable to 30 Gy in 10 fractions. Methods: A total 60 patients were divided equally into Arm A and Arm B with locally advanced stage IIIA, and stage IIIB NSCLC patients with the objective to compare palliation of symptoms and to assess the toxicity profile. This Quasi Experimental study was carried out from January 2018 to December 2018 in the department of Radiation oncology, National Institute of Cancer Research and Hospital. Cases of Arm A were treated with 17 Gy radiotherapy in 2 fractions and those of Arm B were treated with 30 Gy radiotherapy in 10 fractions. Results: The mean age was 49.3±8.8 and 52.2±8.1 years for the Arm- A and the Arm-B respectively. Most patients in both groups were males, 80% in group A and 90% in group B. Adenocarcinoma (Arm A-70%, Arm B- 66.7%) was the most common pathological subtype in both groups, followed by Squamous cell carcinoma (30%, 33.3% respectively). This study showed that there was a significant palliation of these symptoms following radiotherapy as reported by patients and as assessed clinically with no statistically significant difference between two Arms. Hemoptysis had the highest rate of improvement, 100% in both arms and improvement in chest pain by 83.3% in arm A and 70% in Arm B. Cough was improved in 83.3% and 67.7% and dyspnea was palliated in 80.0% and 70.0% of patients in Arm A and Arm B, respectively as per clinical assessment of the patients. The early toxicities in both arms had no significant difference. Patients with locally advanced inoperable NSCLC have poor prognosis and less survival. The first goal was acceptable symptoms control as cough, dyspnoea, haemoptysis and chest pain. Conclusion: The result of this study showed that a significant palliation of symptoms with minimum toxicities improving quality of life following radiotherapy as reported by patients also assessed clinically and radiographically with no statistically significant difference among both arms. VL - 8 IS - 2 ER -
Information
Email: